Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rapid Micro Biosystems (RPID) EBIT (2020 - 2025)

Rapid Micro Biosystems (RPID) has disclosed EBIT for 6 consecutive years, with -$12.2 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 19.38% to -$12.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$47.4 million through Dec 2025, up 5.06% year-over-year, with the annual reading at -$47.4 million for FY2025, 5.06% up from the prior year.
  • EBIT hit -$12.2 million in Q4 2025 for Rapid Micro Biosystems, down from -$11.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$9.7 million in Q1 2021 to a low of -$17.3 million in Q4 2022.
  • Historically, EBIT has averaged -$13.2 million across 5 years, with a median of -$12.8 million in 2024.
  • Biggest five-year swings in EBIT: tumbled 80.67% in 2021 and later rose 29.39% in 2023.
  • Year by year, EBIT stood at -$14.6 million in 2021, then decreased by 18.58% to -$17.3 million in 2022, then rose by 29.39% to -$12.2 million in 2023, then grew by 16.07% to -$10.2 million in 2024, then decreased by 19.38% to -$12.2 million in 2025.
  • Business Quant data shows EBIT for RPID at -$12.2 million in Q4 2025, -$11.4 million in Q3 2025, and -$12.1 million in Q2 2025.